Acute pulmonary attack Bronchospasm Exacerbation COPD
Conditions
Interventions
Three doses of intravenous 0,5 mg/kg enoximone, leading to a total dose of 1.5
mg/kg enoximone
Sponsors
Rijnstate Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with an AE-COPD wherefore intubation occurred within 24 hours before enrollment.
Exclusion criteria
Exclusion criteria: Patients with known asthma or interstitial lung disease (ILD) Known neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Guillain-Barre and Dementia Hypertrophic obstructive cardiomyopathy (HOCM) Severe aortic stenosis with aortic valve area 1.5 Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Auto-PEEP | — |
Secondary
| Measure | Time frame |
|---|---|
| Respiratory parameters: - Lungcompliance in L/cmH2O - Airway resistance in cmH2O/L/s - VCO2 - etCO2 - FiO2 Cardiac parameters: - RVSP - Cardiac output - TAPSE - MAPSE - Ejection Fraction of the Left Ventricle Arterial blood gas analysis (2 ml of blood, obtained through an arterial cannula): - pH, PaCO2, PaO2, saturation, lactate, base excess, Vital Signs: - Occurrence of adverse side effects such as (supraventricular) arrhythmics and hypotension | — |
Countries
Netherlands
Outcome results
None listed